Risk Reduction in Peanut Immunotherapy

Benjamin C. Remington; Joseph L. Baumert

doi:10.1016/j.iac.2019.09.012

Risk Reduction in Peanut Immunotherapy

Benjamin C. Remington, Joseph L. Baumert

Food Science and Technology

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Complete avoidance of peanut is difficult and accidental reactions are known to occur. Immunotherapy for peanut allergy is a potential treatment option being developed with the potential to reduce the risk of accidental reactions to peanut in the community. This article covers the epidemiology of unexpected allergic reactions to peanut, and outlines definitions of risk and risk reduction with quantitative risk assessment examples. Well-acknowledged future areas of research still exist, especially in the area of longer-term clinical trials or commercial data, which will strengthen the knowledge surrounding risk and potential options for risk reduction in those with peanut allergy.

Original language	English (US)
Pages (from-to)	187-200
Number of pages	14
Journal	Immunology and Allergy Clinics of North America
Volume	40
Issue number	1
DOIs	https://doi.org/10.1016/j.iac.2019.09.012
State	Published - Feb 2020

Keywords

Food allergy
Peanut
Peanut immunotherapy
Quantitative risk assessment
Quantitative risk reduction
Relative risk reduction
Risk assessment
Risk reduction

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/j.iac.2019.09.012

Cite this

@article{df735211deca4fab80bb0e0529b1cd6e,

title = "Risk Reduction in Peanut Immunotherapy",

abstract = "Complete avoidance of peanut is difficult and accidental reactions are known to occur. Immunotherapy for peanut allergy is a potential treatment option being developed with the potential to reduce the risk of accidental reactions to peanut in the community. This article covers the epidemiology of unexpected allergic reactions to peanut, and outlines definitions of risk and risk reduction with quantitative risk assessment examples. Well-acknowledged future areas of research still exist, especially in the area of longer-term clinical trials or commercial data, which will strengthen the knowledge surrounding risk and potential options for risk reduction in those with peanut allergy.",

keywords = "Food allergy, Peanut, Peanut immunotherapy, Quantitative risk assessment, Quantitative risk reduction, Relative risk reduction, Risk assessment, Risk reduction",

author = "Remington, {Benjamin C.} and Baumert, {Joseph L.}",

note = "Funding Information: Dr B.C. Remington is the Managing Director of the Remington Consulting Group B.V. and is an Adjunct Assistant Professor of Food Science & Technology at the University of Nebraska-Lincoln; Dr B.C. Remington reports grants, travel support, and consulting fees from DBV Technologies. Dr J.L. Baumert is an Associate Professor of Food Science & Technology and Co-Director of the Food Allergy Research and Resource Program (FARRP) at the University of Nebraska-Lincoln; Dr J.L. Baumert reports travel support and consulting fees from DBV Technologies. Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2020",

month = feb,

doi = "10.1016/j.iac.2019.09.012",

language = "English (US)",

volume = "40",

pages = "187--200",

journal = "Immunology and Allergy Clinics of North America",

issn = "0889-8561",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Risk Reduction in Peanut Immunotherapy

AU - Remington, Benjamin C.

AU - Baumert, Joseph L.

N1 - Funding Information: Dr B.C. Remington is the Managing Director of the Remington Consulting Group B.V. and is an Adjunct Assistant Professor of Food Science & Technology at the University of Nebraska-Lincoln; Dr B.C. Remington reports grants, travel support, and consulting fees from DBV Technologies. Dr J.L. Baumert is an Associate Professor of Food Science & Technology and Co-Director of the Food Allergy Research and Resource Program (FARRP) at the University of Nebraska-Lincoln; Dr J.L. Baumert reports travel support and consulting fees from DBV Technologies. Publisher Copyright: © 2019 Elsevier Inc.

PY - 2020/2

Y1 - 2020/2

N2 - Complete avoidance of peanut is difficult and accidental reactions are known to occur. Immunotherapy for peanut allergy is a potential treatment option being developed with the potential to reduce the risk of accidental reactions to peanut in the community. This article covers the epidemiology of unexpected allergic reactions to peanut, and outlines definitions of risk and risk reduction with quantitative risk assessment examples. Well-acknowledged future areas of research still exist, especially in the area of longer-term clinical trials or commercial data, which will strengthen the knowledge surrounding risk and potential options for risk reduction in those with peanut allergy.

AB - Complete avoidance of peanut is difficult and accidental reactions are known to occur. Immunotherapy for peanut allergy is a potential treatment option being developed with the potential to reduce the risk of accidental reactions to peanut in the community. This article covers the epidemiology of unexpected allergic reactions to peanut, and outlines definitions of risk and risk reduction with quantitative risk assessment examples. Well-acknowledged future areas of research still exist, especially in the area of longer-term clinical trials or commercial data, which will strengthen the knowledge surrounding risk and potential options for risk reduction in those with peanut allergy.

KW - Food allergy

KW - Peanut

KW - Peanut immunotherapy

KW - Quantitative risk assessment

KW - Quantitative risk reduction

KW - Relative risk reduction

KW - Risk assessment

KW - Risk reduction

UR - http://www.scopus.com/inward/record.url?scp=85075190416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075190416&partnerID=8YFLogxK

U2 - 10.1016/j.iac.2019.09.012

DO - 10.1016/j.iac.2019.09.012

M3 - Review article

C2 - 31761118

AN - SCOPUS:85075190416

SN - 0889-8561

VL - 40

SP - 187

EP - 200

JO - Immunology and Allergy Clinics of North America

JF - Immunology and Allergy Clinics of North America

IS - 1

ER -

Risk Reduction in Peanut Immunotherapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this